Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MDAI
MDAI logo

MDAI Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
1.915
Open
1.870
VWAP
1.86
Vol
224.10K
Mkt Cap
58.24M
Low
1.830
Amount
416.46K
EV/EBITDA(TTM)
--
Total Shares
31.82M
EV
55.95M
EV/OCF(TTM)
--
P/S(TTM)
3.13
Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image.
Show More

Events Timeline

(ET)
2026-05-26
07:10:00
Spectral AI's DeepView System Receives FDA De Novo Classification
select
2026-04-08 (ET)
2026-04-08
08:50:00
Spectral AI Appoints David McGuire as CFO
select
2026-03-24 (ET)
2026-03-24
16:30:00
Spectral AI Q4 Revenue $3.8M Beats Expectations
select
2026-03-24
16:30:00
FY26 Revenue Outlook Reflects Development of DeepView System
select
2026-03-18 (ET)
2026-03-18
16:40:00
Spectral AI Secures $31.7M Funding from BARDA
select
2026-02-10 (ET)
2026-02-10
08:40:00
Spectral AI Appoints Vincent Capone as CEO
select
2025-11-11 (ET)
2025-11-11
16:01:47
Spectral AI Announces Q3 Earnings Per Share of 13 Cents, Exceeding Consensus Estimate of 9 Cents
select
2025-10-23 (ET)
2025-10-23
08:34:14
Spectral AI sets share price at $1.90 for 4 million shares in offering
select

News

NASDAQ.COM
9.0
05-26NASDAQ.COM
Spectral AI Shares Drop 12% After FDA De Novo Classification
  • Stock Decline: Shares of Spectral AI, Inc. fell approximately 12% in Tuesday morning trading, currently priced at $2.34, down 12.72% from the previous close of $2.68, indicating a negative market reaction to the news.
  • FDA Approval: The company announced that its DeepView System received De Novo Classification from the U.S. Food and Drug Administration, allowing it to be used in burn care across various settings, paving the way for future commercial distribution activities.
  • Historical Trading Range: Over the past year, Spectral AI's stock has fluctuated between $1.18 and $3.21, with the current price nearing the year's low, reflecting market concerns about the product's prospects.
  • Commercial Activity Launch: With the De Novo Classification, Spectral AI is authorized to commence commercial distribution activities in the U.S., a significant development that, despite its importance, has not been positively reflected in market reactions.
Newsfilter
8.5
05-26Newsfilter
Spectral AI Receives FDA De Novo Classification for DeepView System
  • FDA Milestone: Spectral AI's DeepView System has received De Novo classification from the FDA, marking a significant advancement in the medical diagnostics field and is expected to accelerate the company's commercial distribution activities in the U.S., thereby enhancing its competitiveness in the trauma care market.
  • Technological Innovation: The DeepView System combines multispectral imaging with a proprietary AI algorithm, enabling image acquisition in 0.2 seconds and processing within 20 to 25 seconds, providing clinicians with rapid, data-driven assessments of wound healing potential, significantly improving treatment decision efficiency.
  • Market Potential: Designed to redefine the standard of care in burn treatment, the system is anticipated to deliver value across the healthcare ecosystem by improving patient outcomes and reducing costs, further solidifying the company's leadership position in the medical technology sector.
  • Strategic Support: The project is partially funded by the U.S. Department of Health and Human Services and the Biomedical Advanced Research and Development Authority (BARDA), highlighting government support for innovative medical technologies, which may provide a strong backing for Spectral AI's future expansion and development.
Globenewswire
3.5
05-13Globenewswire
MindBio Leverages AI Voice Analysis for Impairment Detection
  • Technological Innovation: MindBio Therapeutics is developing a platform that combines AI and voice analysis to detect impairment from multiple substances in real-time, addressing a significant gap in existing detection technologies and potentially enhancing public safety and health response capabilities.
  • Market Potential: The company targets a market of approximately $47 billion in workplace safety and substance testing, aiming to drive industry efficiency and compliance through the application of non-invasive detection technologies to meet growing market demands.
  • Scientific Basis: MindBio's technology is grounded in clinical trial data from over 50 million data points, enabling efficient identification of impairment signatures from various substances, providing a more comprehensive assessment than traditional single-substance tests, which holds significant clinical and societal implications.
  • Industry Impact: By facilitating real-time impairment detection, MindBio's technology could reduce traffic and workplace accidents, enhancing overall societal safety, aligning with the global urgent need for rapid, scalable detection solutions.
Newsfilter
3.5
05-13Newsfilter
MindBio Leverages AI Voice Analysis for Impairment Detection
  • Technological Innovation: MindBio Therapeutics is developing a platform that combines AI and voice analysis to detect impairment from multiple substances in real-time, addressing a significant gap in existing detection technologies and is expected to greatly enhance public and workplace safety.
  • Market Potential: The company is targeting a market of approximately $47 billion in workplace safety and substance testing, with growing demand for efficient and scalable detection solutions, positioning MindBio's technology for widespread application across various industries.
  • Scientific Foundation: MindBio's technology is grounded in clinical trial data from over 50 million data points, enabling efficient identification of intoxication states and providing a more comprehensive assessment compared to traditional single-substance tests, with high detection accuracy.
  • Social Impact: By reducing traffic accidents and workplace incidents caused by intoxication, MindBio's non-invasive detection methods have the potential to improve public health globally and lower the societal costs associated with substance use.
Newsfilter
1.0
04-20Newsfilter
Spectral AI Announces 2026 Annual Stockholders Meeting
  • Meeting Announcement: Spectral AI will hold its 2026 Annual Stockholders Meeting on May 29, 2026, at 9:30 a.m. CDT, with voting rights limited to stockholders of record as of April 1, 2026, ensuring shareholder engagement and decision-making authority.
  • Voting Options: Shareholders can attend in person at the corporate headquarters or participate virtually by registering in advance, providing flexible participation options aimed at increasing voter turnout and engagement.
  • Disclosure of Information: Important details regarding the Annual Meeting and the matters to be considered have been disclosed in the Definitive Proxy Statement filed with the SEC on April 16, 2026, ensuring shareholders are well-informed about the meeting's agenda.
  • Company Overview: Spectral AI focuses on medical diagnostics, aiming to enhance treatment decisions in wound care through its DeepView System, which seeks to provide rapid and accurate treatment insights to improve patient outcomes and reduce healthcare costs.
Newsfilter
8.5
04-09Newsfilter
Spectral AI to Showcase DeepView System at American Burn Association Annual Meeting
  • Event Participation: Spectral AI will showcase its DeepView® System at the American Burn Association Annual Meeting from April 14-17, 2026, in Orlando, Florida, attracting over 2,200 clinicians and researchers, which will enhance the company's influence in the burn care industry.
  • Product Demonstration: The DeepView System combines multispectral imaging with a proprietary AI algorithm to rapidly assess the healing potential of burn wounds, enabling clinicians to make faster treatment decisions, which is expected to significantly improve patient outcomes and reduce healthcare costs.
  • FDA Application Progress: Spectral AI submitted its De Novo 510(k) marketing clearance application for the DeepView System to the FDA in June 2025, and if approved, it will further accelerate the product's market entry and strengthen the company's competitive position in medical diagnostics.
  • Industry Recognition: Spectral AI has been named one of TIME's Top HealthTech Companies of 2025, highlighting its leadership in medical technology innovation and is expected to attract more investor interest in its future growth potential.
Wall Street analysts forecast MDAI stock price to rise
2 Analyst Rating
Wall Street analysts forecast MDAI stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
3.00
Averages
4.50
High
6.00
Current: 0.000
sliders
Low
3.00
Averages
4.50
High
6.00
BTIG
Buy
maintain
$3 -> $4
AI Analysis
2026-05-26
Reason
BTIG
Price Target
$3 -> $4
AI Analysis
2026-05-26
maintain
Buy
Reason
BTIG raised the firm's price target on Spectral AI to $4 from $3 and keeps a Buy rating on the shares after the company announced it received FDA clearance for the DeepView System for Burn Centers, Trauma Centers, and Emergency Departments. FDA clearance is a significant milestone for the company as the DeepView System has been in development and clinical investigation for numerous years, the analyst tells investors in a research note.

Valuation Metrics

The current forward P/E ratio for Spectral AI Inc (MDAI.O) is 52.36, compared to its 5-year average forward P/E of 2.10. For a more detailed relative valuation and DCF analysis to assess Spectral AI Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
2.10
Current PE
52.36
Overvalued PE
14.34
Undervalued PE
-10.15

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-21.08
Current EV/EBITDA
-5.39
Overvalued EV/EBITDA
1.91
Undervalued EV/EBITDA
-44.07

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
5.68
Current PS
2.58
Overvalued PS
11.00
Undervalued PS
0.35

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

high volume low float stocks today
Intellectia · 31 candidates
Market Cap: 50.00M - 5.00BRegion: USPrice: $1.00 - $50.00Volume: >= 1,000,000Relative Vol: >= 2Floating Shares: <= 30,000,000
Ticker
Name
Market Cap$
top bottom
BATL logo
BATL
Battalion Oil Corp
95.48M
PAYS logo
PAYS
Paysign Inc
283.70M
FUBO logo
FUBO
FuboTV Inc
1.18B
SLND logo
SLND
Southland Holdings Inc
71.43M
KSCP logo
KSCP
Knightscope Inc
77.31M
AGRO logo
AGRO
Adecoagro SA
2.10B
stocks to buy under 2 $ today
Intellectia · 46 candidates
Market Cap: >= 50.00MPrice: $0.20 - $2.00Rsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20
Ticker
Name
Market Cap$
top bottom
PROP logo
PROP
Prairie Operating Co
84.70M
REI logo
REI
Ring Energy Inc
301.53M
MVIS logo
MVIS
MicroVision Inc
215.19M
BLND logo
BLND
Blend Labs Inc
442.24M
HAIN logo
HAIN
Hain Celestial Group Inc
56.02M
UPXI logo
UPXI
Upexi Inc
81.62M

Whales Holding MDAI

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Spectral AI Inc (MDAI) stock price today?

The current price of MDAI is 1.83 USD — it has decreased -1.61

What is Spectral AI Inc (MDAI)'s business?

Spectral AI, Inc. is a predictive artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company's DeepView platform is a predictive device that offers clinicians an objective and immediate assessment of a wound healing potential prior to treatment or other medical intervention. DeepView platform that combines AI algorithms and multispectral imaging (MSI) imaging for an assessment of wound healing potential. It is non-invasive, non-radiation, non-laser and does not require the use of injectable dye. The DeepView AI- Burn software is used with the DeepView SnapShot imaging device, and it is intended to be used as an adjunctive tool to aid healthcare providers in the assessment of burn wound healing potential by differentiating non-healing from healing burned tissue within an image.

What is the price predicton of MDAI Stock?

Wall Street analysts forecast MDAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDAI is4.50 USD with a low forecast of 3.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Spectral AI Inc (MDAI)'s revenue for the last quarter?

Spectral AI Inc revenue for the last quarter amounts to 3.99M USD, decreased -40.50

What is Spectral AI Inc (MDAI)'s earnings per share (EPS) for the last quarter?

Spectral AI Inc. EPS for the last quarter amounts to -0.11 USD, decreased -191.67

How many employees does Spectral AI Inc (MDAI). have?

Spectral AI Inc (MDAI) has 65 emplpoyees as of June 11 2026.

What is Spectral AI Inc (MDAI) market cap?

Today MDAI has the market capitalization of 58.24M USD.